We also identified regulatory mechanisms specific to each IBD subtype that are potential therapeutic targets: in CD and SI-NET, IL-6 and ciliary-dependent signaling pathways exacerbates fibrosis, and in UC and SI-NET, macrophages and the NCAM signaling pathway, though less extensively studied, also promote ECM accumulation. Here, IL6 is linked to inflammatory bowel disease.